Preview

Колопроктология

Расширенный поиск

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ БОЛЕЗНИ КРОНА У ВЗРОСЛЫХ (ПРОЕКТ)

https://doi.org/10.33878/2073-7556-2020-19-2-8-38

Полный текст:

Об авторе

статья Редакционная

Россия


Список литературы

1. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30.

2. Reinisch W, Rutgeerts P, Panaccione R, D'Haens G, et al. Identifying appropriate dichotomizing points for SES-CD to predict long-term clinical remission for adalimumab-treated patients with Crohn's disease. J Crohns Colitis. 2010;4:P045.

3. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. Миклош, 2008.

4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-17.

5. Гастроэнтерология. Национальное руководство / Под ред. В.Т. Ивашкина, Т.Л. Лапиной. ГЭОТАР Медиа, 2008; 754 c.

6. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of infl ammatory bowel diseases. Gastroenterology. 2011;140:1785-94.

7. Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П., Алексеенко С.А., и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445-463. https://doi.org/10.18786/2072-05052018-46-5-445-463.

8. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A): 5-36.

9. Cosnes J, Cattan S, Blain A, Beaugerie L, et al. Long-term evo lution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-50.

10. Белоусова Е.А. Рекомендации по диагностике и лечению болезни Крона. Фарматека. 2009; № 13, c. 38-44.

11. Torres J, Bonovas S, Doherty G, Kucharzik T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 2020; 4(1): 4-22.

12. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar;70(3):439-44.

13. Pimentel AM, Rocha R, Santana GO. Crohn’s disease of esophagus, stomach and duodenum. World J Gastrointest Pharmacol Ther. 2019; 10 (2): 35-49.

14. Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных про явлений воспалительных заболеваний кишечника. Фарматека. 2011; № 15, c. 44-49.

15. Щукина О.Б. Перианальная болезнь Крона: диагностика и медикаментозная терапия. Фарматека. 2008; № 13, c. 22-30.

16. Gecse KB, Bemelman W, Kamm MA, Stoker J, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014;63(9):1381-92.

17. Steinhart AH, Panaccione R, Targownik L, et al. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus . Inflamm Bowel Dis. 2019 Jan 1;25(1):1-13. doi: 10.1093/ibd/izy247.

18. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology. 2008;247(1):64-79.

19. Чашкова Е.Ю., Владимирова А.А., Неустроев В.Г. и соавт. Воспалительные заболевания толстой кишки – аспекты диагностики. Бюллетень Восточно-Сибирского научного центра СОРАМН. 2011; № 4-2, c. 209-221.

20. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.

21. Справочник по колопроктологии под редакцией проф. Ю.А. Шелыгина, проф Л.А. Благодарного. «Литтерра», 2012; c. 460-522.

22. Lucendo AJ, Arias Á , Roncero Ó, Hervías D, et al. Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients . Sao Paulo Med J. 2014;132(3):140-6.

23. Irwin JR, Ferguson E, Simms LA, Hanigan K, et al. Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's Disease. Dig Dis Sci. 2019 Feb;64(2):503-517.

24. Feng JR, Qiu X, Wang F, Chen PF, et al. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract. 2017;2017:3526460. doi: 10.1155/2017/3526460.

25. Archampong EQ, Harris J, Clark CG. The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro. Gut. 1972 Nov;13(11):880-6.

26. Maharshak N, Arbel Y, Gal-Oz A, Rogowski O, et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis. 2008 Aug;9(3):140-3.

27. Weber P, Husemann S, Vielhaber H, Zimmer KP, et al. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999 Apr;28(4):418-22.

28. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-665.

29. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-37.

30. Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007; 5: 345-351.

31. Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339-344.

32. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1432-42.

33. Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443-50.

34. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1432-42.

35. Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443-50.

36. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of micro biological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775-8.

37. Axelrad JE1, Joelson A, Green PHR, Lawlor G, et al. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct;113(10):1530-1539. doi: 10.1038/s41395-018-0211-8.

38. Nolan DJ. Radiology of inflammatory bowel disease. Br J Hosp Med. 1986 Aug;36(2):128-32.

39. Long B, Robertson J, Koyfman A. Emergency Medicine Evaluation and Management of Small Bowel Obstruction: EvidenceBased Recommendations. J Emerg Med. 2019 Feb;56(2):166-176. doi: 10.1016/j.jemermed.2018.10.024. Epub 2018 Dec 6.

40. Coremans G, Rutgeerts P, Geboes K, et al. The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn's disease. Gastrointest Endosc. 1984;30:167-72.

41. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018.

42. Cameron DJ. Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn's disease: a prospective study. J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):355-8.

43. Annunziata ML, Caviglia R, Papparella LG. Cicala M. Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci. 2012;57:1618-1623.

44. Gourtsoyiannis NC, Grammatikakis J, Papamastorakis G, et al. Imaging of small intestinal Crohn's disease: comparison between MR enteroclysis and conventional enteroclysis. Eur Radiol. 2006;16:1915-25.

45. Bettenworth D, Bokemeyer A, Baker M, Mao R, et al. Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut. 2019 June; 68(6):1115-1126.

46. Chidi VN, Schwartz DA. Imaging of perianal fistulizing Crohn's disease. Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):797-806. doi: 10.1586/17474124.2015.1031110. Epub 2015 Mar 30.

47. Sheedy SP, Bruining DH, Dozois EJ, Faubion WA, et al. MR Imaging of Perianal Crohn Disease. Radiology. 2017 Mar;282(3):628-645. doi: 10.1148/radiol.2016151491.

48. Gasche C, Schober E, Turetschek K. Small bowel barium studies in Crohn's disease. Gastroenterology. 1998 Jun;114(6):1349.

49. Nolan DJ, Piris J. Crohn's disease of the small intestine: a comparative study of the radiological and pathological appearances. Clin Radiol. 1980 Sep;31(5):591-6.

50. Портной Л.М., Исаков В.А., Казанцева И.А. Современная лучевая диагностика болезни Крона тонкой кишки. Вестник рентгенол., радиол. 2001; № 5. c. 10-16.

51. Тертычный А.С., Андреев А.И., Гебоэс К. Современные подходы к морфологической диагностике воспалительных заболеваний кишечника на материале эндоскопических биопсий. Архив патологии. 2011; т. 73; № 1, c. 40-47.

52. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology. 2005;236:95-101.

53. Воробьев Г.И., Орлова Л.П., Самсонова Т.В., Капуллер Л.Л., и соавт. Возможности ультразвукового исследования в диагностике болезни крона. Ультразвуковая и функциональная диагностика. 2010; № 1, c. 29-36.

54. Самсонова Т.В., Орлова Л.П. Ультразвуковая семиотика болезни Крона тонкой кишки. Колопроктология. 2014; № 1(47), c. 60-68.

55. Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol. 2010;105:1240-1248 [quiz 1249].

56. Spada C, Riccioni ME, Costamagna G. Patients with known small bowel stricture or with symptoms of small bowel obstruction secondary to Crohn’s disease should not perform video capsule endoscopy without previously tested for small bowel patency. Am J Gastroenterol. 2007; 102:1542-3.

57. Spada C, Shah SK, Riccioni ME et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol. 2007; 42:576-82.

58. Schulz C, Mönkemüller K, Salheiser M, et al. Double-balloon enteroscopy in the diagnosis of suspected isolated Crohn's disease of the small bowel. Dig Endosc. 2014 Mar;26(2):236-42. doi: 10.1111/den.12142. Epub 2013 Jul 16.

59. American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116(6):1461-3.

60. Корнеева О.И., Ивашкин В.Т. Антибиотико-ассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007; т. 17, № 3, c. 65-71.

61. Coward S, Kuenzig ME, Hazlewood G, Clement F, et al.Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis. Inflamm Bowel Dis. 2017 Mar;23(3):461-472. doi: 10.1097/MIB.0000000000001023.

62. Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2015 Jun 3;(6):CD000296. doi: 10.1002/14651858.CD000296.pub4.

63. Carter MJ, Lobo AJ, Travis SP. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1-V16.

64. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;34:565-72 discussion 572-3.97.

65. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2003(4):CD000301.

66. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008:CD000296.

67. Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2016 Oct 26;10:CD000545.

68. Herfarth HH, Kappelman MD, Long MD, et al. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:224-33.

69. McDonald JW1, Wang Y, Tsoulis DJ, MacDonald JK, et al. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2014 Aug 6;(8):CD003459. doi: 10.1002/14651858.CD003459.pub4.

70. Pearson DC, May GR, Fick GR, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000(2):CD000067.

71. Chande N, Patton PH, Tsoulis DJ, Thomas BS, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2015 Oct 30;(10):CD000067.

72. Qiu Y, Chen BL, Feng R, Zhang SH, et al. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol. 2018 Mar;33(3):664-670. doi: 10.1111/jgh.14000.

73. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;2:CD006792.

74. Ho GT, Chiam P, Drummond H, Loane J, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-30.

75. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990 Aug;19(2):126-46.

76. Khan KJ, Ullman TA, Ford AC, Abreu MT, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol. 2011;106:661-73.

77. Ohkusa T, Kato K, Terao S, Chiba T, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a doubleblind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820-9.

78. Ledder O, Turner D. Antibiotics in IBD: Still a Role in the Biological Era? Inflamm Bowel Dis. 2018 Jul 12;24(8):1676-1688.

79. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328-32

80. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology. 2015 Feb;148(2):344-54.

81. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394-409.

82. Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017 May;45(10):1291-1302.

83. Hazlewood GS, Rezaie A, Borman M, Panaccione R, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Aliment Pharmacol Ther. 2017 May;45(10):12911302. doi: 10.1111/apt.14030. Epub 2017 Mar 22.

84. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;1:CD006893.

85. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.

86. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 Nov 17;375(20):1946-1960.

87. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-95.

88. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathio prine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054-61.

89. Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Gut. 2008;57 Suppl II:A1.

90. Colombel JF, Adedokun OJ, Gasink C, Gao LL, et al. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1525-1532.e1. doi: 10.1016/j.cgh.2018.09.033. Epub 2018 Sep 26.

91. Singh S, George J, Boland BS, Vande Casteele N, et al. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Metaanalysis. J Crohns Colitis. 2018 May 25;12(6):635-643. doi: 10.1093/ecco-jcc/jjy004.

92. Gecse KB, Végh Z, Lakatos PL. Optimizing biological therapy in Crohn's disease. Expert Rev Gastroenterol Hepatol. 2016;10(1):37-45. doi: 10.1586/17474124.2016.1096198. Epub 2015 Oct 16.

93. Kawalec P, Moćko P. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients. J Comp Eff Res. 2018 Feb;7(2):101-111. doi: 10.2217/cer2017-0041. Epub 2017 Nov 8.

94. Bressler B, Yarur A, Kopylov U, Bassel M, et al. United European Gastroenterol J. 2019:7(8 Suppl):624. Abstract P1091.

95. Gisbert JP1, Mar ín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4.

96. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893.

97. Strong SA, Koltun WA, Hyman NH, Buie WD. Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the surgical management of Crohn’s disease. Dis Colon Rectum. 2007;50:1735-46.

98. Adamina M, Bonovas S, Raine T, Spinelli A, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. Journal of Crohn's and Colitis. 2020;14(2):155-168 doi:10.1093/ecco-jcc/jjz187.

99. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 3;7:CD008870. doi: 10.1002/14651858.CD008870.pub2.

100. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=33aa4f17-be46-459a-b95a-c258bb4e29b2&t=

101. Шапина М.В., Халиф И.Л., Нанаева Б.А. Применение цертолизумаба пэгола при болезни Крона. Обзор литературы. Колопроктология. 2016; № 3(57), c .102-108.

102. Wang X, Shen B. Advances in Perianal Disease Associated with Crohn's Disease-Evolving Approaches. Gastrointest Endosc Clin N Am. 2019 Jul;29(3):515-530. doi: 10.1016/j.giec.2019.02.011.

103. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328-32.

104. Нанаева Б.А., Варданян А.В. Халиф И.Л. Эффективность терапии такролимусом у больных с перианальными поражениями при болезни Крона. Терапевтический архив. 2015;87(6):83-87 doi: 10.17116/terarkh201587683-87.

105. Puolanne AM, Kolho KL, Alfthan H, Färkkil ä M. Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. Scand J Gastroenterol. 2019 Jul;54(7):849-854. doi: 10.1080/00365521.2019.1618910. Epub 2019 Jul 2.

106. Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019 Jun;15(6):667-677. doi: 10.1080/1744666X.2019.1593140. Epub 2019 Mar 20.

107. Князев О.В., Каграманова А.В., Корнеева И.А. и соавт. Значение фекального кальпротектина в мониторинге активности воспалительных заболеваний кишечника. Терапевтический архив. 2019; № 91(4), с. 53-61. DOI: 10.26442/00403660.2019.04.000229.

108. Vernia F, Di Ruscio M, Stefanelli G, Viscido A, et al. Is fecal calprotectin an accurate marker in the management of Crohn's disease? J Gastroenterol Hepatol. 2020 Mar;35(3):390-400. doi: 10.1111/jgh.14950. Epub 2019 Dec 18.

109. Agrawal M, Colombel JF. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat? Gastrointest Endosc Clin N Am. 2019 Jul;29(3):421-436. doi: 10.1016/j.giec.2019.02.004. Epub 2019 Apr 6.

110. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25.

111. Luglio G, Giglio MC, Rispo A, Bucci C, et al. Diagnostic Accuracy of 3-Dimensional Endoanal Ultrasound in Identifying Perianal Crohn's Fistulas. Dis Colon Rectum. 2018 Aug;61(8):931-937. doi: 10.1097/DCR.0000000000001099.

112. Brand EC, Elias SG, Minderhoud IM, et al. Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn's disease. Clin Gastroenterol Hepatol. 2019 Dec 24. pii: S15423565(19)31493-4.

113. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005. 172(9): 1169-227.

114. Rahier JF, Magro F, Abreu C, Armuzzi A, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun;8(6):443-68. doi: 10.1016/j.crohns.2013.12.013. Epub 2014 Mar 6.

115. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-13.

116. Billioud V, Ford AC, Tedesco ED, Colombel JF, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. Journal of Crohn's & colitis. 2013;7(11):853-67.

117. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, et al. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflammatory Bowel Diseases. 2012;18(12):2404-13.

118. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(1):79-92.

119. Yang ZP, Hong L, Wu Q, Wu KC, et al. Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. International Journal Of Surgery. 2014;12(3):224-30.

120. Хачатурова Э.А., Ерошкина Т.Д., Блинова О.В., и соавт. Коррекция нарушений метаболизма в раннем послеоперационном периоде при тяжелых формах неспецифического язвенного колита и болезни Крона. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2003, т. 8, № 4, с.63-68.

121. Korzenik JR. Massive lower gastrointestinal hemorrhage in Crohn’s disease. Curr Treat Options Gastroenterol. 2000;3:211-6.

122. Bundred NJ, Dixon JM, Lumsden AB, Gilmour HM, et al. Free perforation in Crohn’s colitis. A ten-year review. Dis Colon Rectum. 1985;28:35-7.

123. Werbin N, Haddad R, Greenberg R, Karin E, et al. Free perforation in Crohn’s disease. Isr Med Assoc J. 2003;5:175-7.

124. Papi C, Festa V, Fagnani C, Stazi A, et al. Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. Dig Liver Dis. 2005;37:247-53.

125. Poggioli G, Stocchi L, Laureti S, Selleri S, et al. Conservative surgical management of terminal ileitis: side-to-side enterocolic anastomosis. Dis Colon Rectum. 1997;40:234-7.

126. Melton GB, Fazio VW, Kiran RP, He J, et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn’s disease: pouch retention and implications of delayed diagnosis. Ann Surg. 2008;248:608-16.

127. Panes J, Bouhnik Y, Reinisch W, Stoker J, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556-85.

128. Варданян А.В., Кашников В.Н., Болихов К.В., Халиф И.Л. Лапароскопическая илеостомия при болезни Крона. Колопроктология. 2011, № 3(37), с. 20-23.

129. Воробьев Г.И., Болихов К.В., Варданян А.В. Место лапароскопической илеостомии в лечении болезни Крона толстой кишки (обзор литературы). Колопроктология. 2009, № 3(29), с. 52-58.

130. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis Colon Rectum. 1996;39:893-8.

131. Simillis C, Purkayastha S, Yamamoto T, Strong SA, et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn's disease. Dis Colon Rectum. 2007;50(10):1674-87.

132. Mege D., Panis Y. Laparoscopic surgery for inflammatory bowel disease. Колопроктология. 2018. № 2(64), c. 14-24.

133. Byrne CM, Solomon MJ, Young JM, Selby W, et al. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum. 2007;50:586-97.

134. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn’s disease: followup of a prospective randomized trial. Surgery. 2008;144:622-7.

135. Щукина О.Б., Собко В.Ю., Горбачева Д.Ш., Григорян В.В., и соавт. Прогнозирование хирургического лечения болезни Крона. Колопроктология. 2015; № 4(54), с. 33-40.

136. Tichansky D, Cagir B, Yoo E, Marcus SM, et al. Strictureplasty for Crohn’s disease: meta-analysis. Dis Colon Rectum. 2000;43:911-9.

137. Reese GE, Purkayastha S, Tilney HS, von Roon A, et al. Strictureplasty vs. resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. 2007;9:686-94.

138. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and metaanalysis. Dis Colon Rectum. 2007;50:1968-86.

139. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 Suppl 1:i36-58.

140. Dietz DW, Laureti S, Strong SA, Hull TL, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn’s disease. J Am Coll Surg. 2001;192:330-7.

141. Шелыгин Ю.А., Халиф И.Л, Кашников В.Н., Болихов К.В., и соавт. Илеостомия в лечении болезни Крона толстой кишки с перианальными поражениями. Колопроктология. 2011; № 3(37), с. 133.

142. van Dongen LM, Lubbers EJC. Perianal fistulas in patients with Crohn’s disease. Arch Surg. 1986;121:1187-90.

143. Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn’s disease. World J Surg. 2000;24:1258-62.

144. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-63.

145. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-17.

146. Полетова А.В., Шапина М.В., Халиф И.Л., Варданян А.В. Эффективность послеоперационной противорецидивной терапии Адалимумабом и азатиоприном при болезни Крона. Колопроктолгия. 2018;№ 2(64), c. 73-77.

147. Peyrin-Biroulet, L., et al., Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009. 104(8): 2089-96.

148. Regueiro M, Schraut W, Baidoo L, Kip KE, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441-50.

149. Terdiman, J.P. Prevention of postoperative recurrence in Crohn's disease. Clin Gastroenterol Hepatol. 2008;6(6):616-20.

150. Papamichael, K., et al., Adalimumab for the prevention and/ or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis. 2012. 6(9): 924-31.

151. Халиф И.Л., Варданян А.В., Шапина М.В., Полетова А.В. Противорецидивная терапия болезни Крона в послеопера ционном периоде (обзор литературы). Колопроктология. 2017;№ 3(61), c. 63-70.

152. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol. 2013 Nov;108(11):1731-42. doi: 10.1038/ajg.2013.287.

153. Yamada A, Komaki Y, Patel N, et al. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509.

154. Lu TX, Cohen RD. Maneuvering Clinical Pathways for Crohn's Disease. Curr Gastroenterol Rep. 2019 Apr 23;21(5):20.

155. Bhattacharya A1, Shen B1, Regueiro M2. Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes? Gastrointest Endosc Clin N Am. 2019 Jul;29(3):487-514. doi: 10.1016/j.giec.2019.02.013.

156. Chu KF, Moran CJ, Wu K, et al. Performance of Surveillance MR Enterography (MRE) in Asymptomatic Children and Adolescents With Crohn's Disease. J Magn Reson Imaging. 2019 Dec;50(6):19551963. doi: 10.1002/jmri.26811.

157. Deepak P, Axelrad JE, Ananthakrishnan AN. The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointest Endosc Clin N Am. 2019 Jul;29(3):447-470. doi: 10.1016/j.giec.2019.02.006.

158. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008;43:948-54.

159. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Алешин Д.В., и соавт. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтеро логии, гепатологии, колопроктологии. 2015; № 5, с. 77-83.

160. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Джанаев Ю.А., и соавт. Роль аноректальной манометрии, БОС-терапии и тибиальной нейромодуляции в диагностике и консервативном лечении анальной инконтиненции у пожилых. Клиническая геронтология. 2015; № 5-6, с. 16-20.

161. Froslie KF, Jahnsen J, Moum BA, VatnMH. Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-22.

162. Lu C, Merrill C, Medellin A, Novak K, et al. Bowel Ultrasound State of the Art: Grayscale and Doppler Ultrasound, Contrast Enhancement, and Elastography in Crohn Disease. J Ultrasound Med. 2019 Feb;38(2):271-288. doi: 10.1002/jum.14920. Epub 2019 Jan 3.

163. Poza-Cordón J, Ripollés-Gonz ález T. Utility of abdominal ultrasonography in the diagnosis and monitoring of inflammatory bowel disease. Rev Esp Enferm Dig. 2014 Jun;106(6):395-408.

164. Calabrese E, Maaser C, Zorzi F, Kannengiesser K, et al. Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflamm Bowel Dis. 2016 May;22(5):1168-83. doi: 10.1097/MIB.0000000000000706.

165. Kucharzik T, Wittig BM, Helwig U, Börner N, et al. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. ClinGastroenterol Hepatol. 2017 Apr;15(4):535-542.e2. doi: 10.1016/j.cgh.2016.10.040. Epub 2016 Nov 14.

166. de Ridder, Lissy; Assa, Amit ; Bronsky, Jiriet al. Use of Biosimilars in Pediatric Inflammatory Bowel Disease . An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2018;68:144-53.


Для цитирования:


КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ БОЛЕЗНИ КРОНА У ВЗРОСЛЫХ (ПРОЕКТ). Колопроктология. 2020;19(2):8-38. https://doi.org/10.33878/2073-7556-2020-19-2-8-38

For citation:


CROHN'S DISEASE. CLINICAL RECOMMENDATIONS (PRELIMINARY VERSION). Koloproktologia. 2020;19(2):8-38. (In Russ.) https://doi.org/10.33878/2073-7556-2020-19-2-8-38

Просмотров: 3238


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7556 (Print)
ISSN 2686-7303 (Online)